Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--May 10, 2024-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 8, 2024, to three new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 323,000 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The awards were granted as an inducement material to the employees entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).
聖地亞哥--(美國商業資訊)--2024年5月10日-- Gossamer Bio, Inc. (Nasdaq: GOSS) 是一家臨床階段的生物製藥公司，專注於開發和商業化用於治療肺動脈高壓 (PAH) 和與間質性肺病 (PH-ILD) 相關的肺動脈高壓 (PH-ILD) 的肺動脈高壓。該公司今天宣佈，戈薩默董事會薪酬委員會批准了對三名非合格股票期權新非執行員工的補助金，該補助金自2024年5月8日起生效獎勵購買Gossamer Bio, Inc.旗下最多32.3萬股公司普通股2023 年就業激勵獎勵計劃（“2023 年激勵計劃”）。根據納斯達克上市規則5635（c）（4），這些獎勵是作爲激勵在Gossamer工作的員工的激勵材料而頒發的。
The options have an exercise price of $0.755 per share, which is equal to the closing price of Gossamer's common stock as reported by The Nasdaq Global Select Market on May 8, 2024. The options have a ten-year term and will vest over four years, with 25% vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive monthly installments thereafter, subject to each employee's continued employment with Gossamer on such vesting dates. The options are subject to the terms and conditions of the 2023 Inducement Plan and the terms and conditions of a stock option agreement covering the grants.
這些期權的行使價爲每股0.755美元，等於納斯達克全球精選市場於2024年5月8日公佈的戈薩默普通股的收盤價。這些期權的期限爲十年，將在四年內歸屬，其中25％在適用的歸屬開始日期一週年之際歸屬，其餘股份將分36次連續每月分期歸屬，前提是每位員工在該歸屬日期繼續在Gossamer工作。期權受2023年激勵計劃的條款和條件以及涵蓋補助金的股票期權協議的條款和條件的約束。
About Gossamer Bio
關於 Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.
Gossamer Bio是一家臨床階段的生物製藥公司，專注於用於治療肺動脈高壓的血清替尼的開發和商業化。其目標是成爲肺動脈高壓的行業領導者，並改善肺動脈高壓患者的生活。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240510801953/en/
For Investors and Media:
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com
對於投資者和媒體：
布萊恩·吉羅多，首席運營官兼首席財務官
Gossamer Bio 投資者關係
ir@gossamerbio.com
Source: Gossamer Bio, Inc.
來源：Gossamer Bio, Inc.